LON:BPCR BioPharma Credit (BPCR) Share Price, News & Analysis GBX 0.97 +0.00 (+0.41%) As of 11:59 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsNews and Trends About BioPharma Credit Stock (LON:BPCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioPharma Credit alerts:Sign Up Key Stats Today's Range 0.96▼ 0.9750-Day Range 0.95▼ 0.9852-Week Range 0.88▼ 1Volume4.40 million shsAverage Volume1.39 million shsMarket Capitalization£10.89 millionP/E Ratio0.09Dividend Yield7.20%Price TargetN/AConsensus RatingN/A Company Overview BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in London, the United Kingdom. Read More Receive BPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPharma Credit and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPCR Stock News HeadlinesMineralys Therapeutics Announces $200 Million Royalty Repurchase and Secures $500 Million Debt FacilityJune 3, 2026 | quiverquant.comQEsperion Therapeutics to Be Acquired by ARCHIMED in Up to $1.1 Billion Transaction, Shareholders to Receive $3.16 Per Share in CashMay 1, 2026 | quiverquant.comQHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 16 at 1:00 AM | Stansberry Research (Ad)UroGen Pharma Ltd. Enhances Financial Position with Amended Loan Agreement for Up to $250 MillionMarch 2, 2026 | quiverquant.comQ3 Undiscovered Gems In The United Kingdom To Consider For Your PortfolioDecember 30, 2025 | finance.yahoo.comExploring Undiscovered Gems in the UK for December 2025December 1, 2025 | uk.finance.yahoo.comUndiscovered Gems In United Kingdom Highlighted By 3 Promising StocksOctober 31, 2025 | finance.yahoo.comBioPharma Credit buys back $50 mln shares, reports $72.8 mln profit in first halfSeptember 22, 2025 | investing.comSee More Headlines BPCR Stock Analysis - Frequently Asked Questions How have BPCR shares performed this year? BioPharma Credit's stock was trading at GBX 0.92 at the beginning of the year. Since then, BPCR stock has increased by 5.9% and is now trading at GBX 0.97. How do I buy shares of BioPharma Credit? Shares of BPCR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of BioPharma Credit own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioPharma Credit investors own include AFPO.L (AFPO), Altius Minerals (ATUSF), NexGen Energy (NXE), Premier African Minerals (PREM) and 21512 (SAT.L) (SAT). Industry, Sector and Symbol Stock ExchangeLON SectorFinance Industry Capital Markets Sub-IndustryAsset Management & Custody Banks Current SymbolLON:BPCR CIKN/A Webwww.bpcruk.com Phone44 13 9247 7500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 11.40 Trailing P/E Ratio0.09 Forward P/E RatioN/A P/E GrowthN/ANet Income£10.42 billion Net Margins92.62% Pretax MarginN/A Return on Equity11.29% Return on Assets4.98% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio14.07 Sales & Book Value Annual Sales£132.06 million Price / Sales0.08 Cash FlowGBX 0.81 per share Price / Cash Flow1.19 Book ValueGBX 98.56 per share Price / Book0.01Miscellaneous Outstanding Shares1,122,193,000Free FloatN/AMarket Cap£10.89 million OptionableNot Optionable Beta0.23 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (LON:BPCR) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
